AUTHOR=Wang Mo-Fei , Li Hao , Cui Jian , Chen Yu-Han , Cui Yong 

TITLE=Effects of Kalimeris indica (L.) Sch Bip on colitis-associated colorectal cancer

JOURNAL=Frontiers in Pharmacology

VOLUME=Volume 13 - 2022

YEAR=2023

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.1119091

DOI=10.3389/fphar.2022.1119091

ISSN=1663-9812

ABSTRACT=Kalimeris indica (L.) Sch Bip (K. indica) is a plant of genus Kalimeris in Asteraceae, and its whole herb can be used as medicine for the treatment of intestinal inflammatory diseases. But the mechanism is not clear. Therefore, this study was designed to explore the mechanism of K. indica (KI) on colitis-associated colorectal cancer. The expression levels of miR-31-5p and proinflammatory factors were detected by using thp1 and Caco2 cells in vitro. KI could restore the upregulation of miR-31-5p level in Caco2 and thp1 cells induced by IL-6 and TNF-α, and maintain the stability of miR-31-5p expression level. In LPS stimulated PMA differentiated thp1 cells, KI restored miR-31-5p expression by downregulating the expression of IL-6 and TNF-α. In vivo test, C57BL/6 mice were used as model animals, and the CAC mouse model was established through the induction of azoxymethane/dextran sulfate sodium. The successfully established CAC mice were treated with water extract of KI through intragastric administration for 5 weeks.  KI could significantly reduce the atypical hyperplasia in colon tissue, and inhibit the expression of proinflammatory factors such as IL-6, TNF, IL-11, IL-7, etc. At the same time, KI could restore the level of miR-31-5p in mice, and therefore the downstream LATS2, to inhibit the occurrence and development of CAC. The above results indicate that KI is a potential effective herb medicine to prevent CAC and lay a theoretical foundation for further research.